The European Medicines Agency (EMA) has awarded the early priority medicines designation, known as e-PRIME, to SPL84, an experimental inhalation therapy designed to treat cystic fibrosis (CF) caused by a specific mutation called 3849+10 kb C-to-T. The EMA grants e-PRIME to investigational medicines that target an unmet medical…